A groundbreaking treatment for aggressive brain tumors has shown promising results in the case of a UK man diagnosed with glioblastoma. Paul Read, a 62-year-old engineer, saw his tumor shrink by 50% following a first-of-its-kind experimental trial at the University College London Hospitals NHS Foundation Trust. Doctors implanted a device under his scalp to deliver low levels of radioactivity directly into the tumor, leading to the significant reduction in size after just six weeks of treatment.
The trial, known as CITADEL-123, is offering hope for patients with this deadly type of cancer, which typically has a poor prognosis. Read, the first patient recruited for the trial, expressed gratitude for the lifeline this treatment provided, given the short expected survival time for his condition.
The medical team, led by Dr. Paul Mulholland, is now planning to treat up to 40 patients in the first phase of the trial, following the success seen in Read’s case. Despite initial symptoms and unsuccessful traditional treatments, Read’s openness to exploring new options ultimately led to this remarkable outcome.
The results of this trial offer a glimmer of hope for patients with glioblastoma, providing a potential new treatment option for a disease that is often fatal. The success of this experimental treatment marks a major breakthrough in the fight against aggressive brain cancers.
Source
Photo credit nypost.com